74 related articles for article (PubMed ID: 17663985)
1. Interferon-gamma expressing EBV LMP2A-specific T cells for cellular immunotherapy.
Sun Q; Brewer N; Dunham K; Chen L; Bao L; Burton R; Lucas KG
Cell Immunol; 2007 Apr; 246(2):81-91. PubMed ID: 17663985
[TBL] [Abstract][Full Text] [Related]
2. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
[TBL] [Abstract][Full Text] [Related]
3. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells.
Sun H; Yao K; Chen Y; Zhou F
Chin Med J (Engl); 2004 Oct; 117(10):1558-63. PubMed ID: 15498383
[TBL] [Abstract][Full Text] [Related]
4. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
[TBL] [Abstract][Full Text] [Related]
5. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
6. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R
Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598
[TBL] [Abstract][Full Text] [Related]
7. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
8. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
[TBL] [Abstract][Full Text] [Related]
9. Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production.
Kim TK; St John LS; Wieder ED; Khalili J; Ma Q; Komanduri KV
J Immunol; 2009 Nov; 183(10):6167-74. PubMed ID: 19841187
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic classification of human CD4+ T cell subsets and their differentiation.
Okada R; Kondo T; Matsuki F; Takata H; Takiguchi M
Int Immunol; 2008 Sep; 20(9):1189-99. PubMed ID: 18635582
[TBL] [Abstract][Full Text] [Related]
12. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.
Diekmann J; Adamopoulou E; Beck O; Rauser G; Lurati S; Tenzer S; Einsele H; Rammensee HG; Schild H; Topp MS
J Immunol; 2009 Aug; 183(3):1587-97. PubMed ID: 19587004
[TBL] [Abstract][Full Text] [Related]
13. Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2.
Lalonde A; Avila-Cariño J; Caruso M; de Campos-Lima PO
Virology; 2007 May; 361(2):253-62. PubMed ID: 17207511
[TBL] [Abstract][Full Text] [Related]
14. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
15. Decreased tumor surveillance after adoptive T-cell therapy.
Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
[TBL] [Abstract][Full Text] [Related]
16. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
[TBL] [Abstract][Full Text] [Related]
17. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.
Chen Y; Sun H; Liu G; Wang B; Wang F; Sun B; Yao K
Cell Mol Immunol; 2009 Aug; 6(4):269-76. PubMed ID: 19728928
[TBL] [Abstract][Full Text] [Related]
18. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
19. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
[TBL] [Abstract][Full Text] [Related]
20. B7-2/CD28 costimulatory pathway in children with atopic dermatitis and its connection with immunoglobulin E, intracellular interleukin-4 and interferon-gamma production by T cells during a 1-month follow-up.
Chernyshov PV
J Eur Acad Dermatol Venereol; 2009 Jun; 23(6):656-9. PubMed ID: 19250325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
